β 1 ‐ and β 2 ‐adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non‐failing adult human heart
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background and purpose: Characterization of human embryonic stem cell‐derived cardiomyocytes (hESC‐CM) in relation to adult myocytes is essential for their future use in transplantation or as a model system. The β‐adrenoceptor pathways, which are known to be effective early in hESC‐CM development, are of major importance because of their control of rate and force of beating, arrhythmia generation and apoptosis/necrosis. We have therefore performed detailed pharmacological analysis of the β‐adrenoceptor responses in developing hESC‐CM. Experimental approach: hESC‐CMs were differentiated from H7 ESCs and studied up to 79 days of differentiation. Rate of beating and time course of contraction and relaxation were measured in superfused preparations. Key results: Responses to the mixed β 1 ‐ and β 2 ‐adrenoceptor agonist isoprenaline were evident from day 10 to day 79. Stability of the responses during an application, for repeated applications on the same experimental day and over the time of development, was determined. Concentrations for half‐maximal response (12.9 n M ) were similar to those from adult human heart, but closer to those obtained from failing rather than normal ventricle. Acceleration of both contraction and relaxation was quantitatively similar to that in adult ventricular myocytes, as was sensitivity to muscarinic inhibition. Use of specific antagonists showed that both β 1 ‐ and β 2 ‐adrenoceptors contributed to contractile responses, as seen with adult myocytes. Conclusions and implications: These data show the compatibility of hESC‐CM with adult human myocardium in terms of β‐adrenoceptor response. The experiments described here also confirm the utility of the hESC‐CM preparation for detailed pharmacological analysis. British Journal of Pharmacology (2008) 153 , 751–759; doi: 10.1038/sj.bjp.0707619 ; published online 14 January 2008
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A fundamental aspect of myocardial function is the response to adrenergic agonists, which has been studied extensively in both rodents and humans, making β-adrenergic response a good test of the ability of our engineered ventricles to recapitulate normal cardiac pharmacology57,58.”
From A tissue-engineered scale model of the heart ventricle (2018) · cites this paper as [58]
Citations
Cites
Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts
Murry, C. E., Soonpaa, M. H., Reinecke, H., Nakajima, H., Nakajima, H. O., Rubart, M., Pasumarthi, K. B. S., Ismail Virag, J., Bartelmez, S. H., Poppa, V., et al. (2004) · Nature · doi:10.1038/nature02446 · Cited by 2,154
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, O., Itskovitz‐Eldor, J., & Gepstein, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12131 · Cited by 1,814
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium
Balsam, L. B., Wagers, A. J., Christensen, J. L., Kofidis, T., Weissman, I. L., & Robbins, R. C. (2004) · Nature · doi:10.1038/nature02460 · Cited by 1,736
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112131 · Cited by 1,536
Mummery, C., Ward-van Oostwaard, D., Doevendans, P., Spijker, R., van den Brink, S., Hassink, R., van der Heyden, M., Opthof, T., Pera, M., de la Riviere, A. B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000068356.38592.68 · Cited by 1,001
Characterization and Enrichment of Cardiomyocytes Derived From Human Embryonic Stem Cells
Xu, C., Police, S., Rao, N., & Carpenter, M. K. (2002) · Circulation Research · doi:10.1161/01.res.0000035254.80718.91 · Cited by 902
Electromechanical integration of cardiomyocytes derived from human embryonic stem cells
Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., Huber, I., Satin, J., Itskovitz-Eldor, J., & Gepstein, L. (2004) · Nature Biotechnology · doi:10.1038/nbt1014 · Cited by 880
He, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800
What Is the Role of β-Adrenergic Signaling in Heart Failure?
Lohse, M. J., Engelhardt, S., & Eschenhagen, T. (2003) · Circulation Research · doi:10.1161/01.res.0000102042.83024.ca · Cited by 764
Brodde, O. E. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06662-1 · Cited by 572
Cited by
Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes
Robertson, C., Tran, D. D., & George, S. C. (2013) · Stem Cells · doi:10.1002/stem.1331 · Cited by 354
Immaturity of Human Stem-Cell-Derived Cardiomyocytes in Culture: Fatal Flaw or Soluble Problem?
Veerman, C. C., Kosmidis, G., Mummery, C. L., Casini, S., Verkerk, A. O., & Bellin, M. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0533 · Cited by 265
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues
Feric, N. T., & Radisic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.019 · Cited by 247
A tissue-engineered scale model of the heart ventricle
MacQueen, L. A., Sheehy, S. P., Chantre, C. O., Zimmerman, J. F., Pasqualini, F. S., Liu, X., Goss, J. A., Campbell, P. H., Gonzalez, G. M., Park, S.-J., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0271-5 · Cited by 227
Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H., Kanda, Y., Kurokawa, J., & Furukawa, T. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.09.010 · Cited by 198
Chen, Q.-Z., Ishii, H., Thouas, G. A., Lyon, A. R., Wright, J. S., Blaker, J. J., Chrzanowski, W., Boccaccini, A. R., Ali, N. N., Knowles, J. C., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.108 · Cited by 174
Self-citationPresent state and future perspectives of using pluripotent stem cells in toxicology research
Wobus, A. M., & Löser, P. (2011) · Archives of Toxicology · doi:10.1007/s00204-010-0641-6 · Cited by 159
Cardiac Differentiation of Pluripotent Stem Cells
Rajala, K., Pekkanen-Mattila, M., & Aalto‐Setälä, K. (2011) · Stem Cells International · doi:10.4061/2011/383709 · Cited by 157
Földes, G., Mioulane, M., Wright, J. S., Liu, A. Q., Novak, P., Merkely, B., Gorelik, J., Schneider, M. D., Ali, N. N., & Harding, S. E. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.029 · Cited by 127
Self-citationViđarsson, H., Hyllner, J., & Sartipy, P. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9113-x · Cited by 128
Current status of drug screening and disease modelling in human pluripotent stem cells
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A., George, V., & Denning, C. (2013) · BioEssays · doi:10.1002/bies.201200053 · Cited by 99
Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening
Dick, E., Rajamohan, D., Ronksley, J., & Denning, C. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381037 · Cited by 110
Towards chamber specific heart-on-a-chip for drug testing applications
Zhao, Y., Rafatian, N., Wang, E. Y., Wu, Q., Lai, B. F. L., Lu, R. X., Savoji, H., & Radisic, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.002 · Cited by 97
Blazeski, A., Zhu, R., Hunter, D. W., Weinberg, S. H., Boheler, K. R., Zambidis, E. T., & Tung, L. (2012) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2012.07.012 · Cited by 78
Mandenius, C., Steel, D. M., Noor, F., Meyer, T. S., Heinzle, E., Asp, J., Arain, S., Kraushaar, U., Bremer, S., Class, R., et al. (2011) · Journal of Applied Toxicology · doi:10.1002/jat.1663 · Cited by 88
Keung, W., Boheler, K. R., & Li, R. A. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt406 · Cited by 87
Pillekamp, F., Haustein, M., Khalil, M., Emmelheinz, M., Nazzal, R., Adelmann, R., Nguemo, F., Rubenchyk, O., Pfannkuche, K., Matzkies, M., et al. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0312 · Cited by 74
Innate Immunity in Human Embryonic Stem Cells: Comparison with Adult Human Endothelial Cells
Földes, G., Liu, A., Badiger, R., Paul‐Clark, M. J., Moreno, L., Lendvai, Z., Wright, J. S., Ali, N. N., Harding, S. E., & Mitchell, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010501 · Cited by 82
Self-citationBaldassarre, A. D., Cimetta, E., Bollini, S., Gaggi, G., & Ghinassi, B. (2018) · Cells · doi:10.3390/cells7060048 · Cited by 78
Rupert, C. E., & Coulombe, K. L. K. (2017) · Stem Cells International · doi:10.1155/2017/7648409 · Cited by 73
Kijlstra, J. D., Hu, D., Mittal, N., Kausel, E., van der Meer, P., Garakani, A., & Domian, I. J. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.017 · Cited by 65
The case for induced pluripotent stem cell‐derived cardiomyocytes in pharmacological screening
Khan, J. M., Lyon, A. R., & Harding, S. E. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02118.x · Cited by 63
Self-citationDunn, K. K., Reichardt, I. M., Simmons, A. D., Jin, G., Floy, M. E., Hoon, K. M., & Palecek, S. P. (2019) · Biotechnology Journal · doi:10.1002/biot.201800725 · Cited by 58
How Carvedilol activates β2-adrenoceptors
Benkel, T., Zimmermann, M., Zeiner, J., Bravo, S., Merten, N., Lim, V., Matthees, E. S. F., Drube, J., Miess, E., Malan, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34765-w · Cited by 62
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes
Giacomelli, E., Mummery, C. L., & Bellin, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2546-5 · Cited by 60
Assessment of cellular toxicity of TiO2nanoparticles for cardiac tissue engineering applications
Jawad, H., Boccaccini, A. R., Ali, N. N., & Harding, S. E. (2010) · Nanotoxicology · doi:10.3109/17435390.2010.516844 · Cited by 58
Self-citationMalandraki-Miller, S., Lopez, C. A., Al-Siddiqi, H., & Carr, C. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00119 · Cited by 53
Šepac, A., Sedlić, F., Si‐Tayeb, K., Lough, J., Duncan, S. A., Bienengraeber, M., Park, F., Kim, J., & Bosnjak, Z. J. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181eff6b7 · Cited by 49
Dyballa, S., Miñana, R. M., Rubio-Brotons, M., Cornet, C., Pederzani, T., Escaramís, G., García-Serna, R., Mestres, J., & Terriente, J. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz165 · Cited by 39
Lopez, C. A., Al-Siddiqi, H., Purnama, U., Iftekhar, S., Bruyneel, A. A. N., Kerr, M. J., Nazir, R., Fialho, M. D. L. S., Malandraki-Miller, S., Alonaizan, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87186-y · Cited by 38
Kadir, S. H. S. A., Ali, N. N., Mioulane, M., Brito‐Martins, M., Abu‐Hayyeh, S., Földes, G., Moshkov, A. V., Williamson, C., Harding, S. E., & Gorelik, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00741.x · Cited by 37
Self-citationVivas, A., IJspeert, C., Pan, J. Y., Vermeul, K., van den Berg, A., Passier, R. C., Keller, S. S., & van der Meer, A. D. (2022) · Advanced Materials Technologies · doi:10.1002/admt.202101355 · Cited by 36
Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity
Denning, C. N., & Anderson, D. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.08.002 · Cited by 36
Liu, J., Zhang, Z., Liu, Y., Guo, C., Gong, Y., Shi, Y., Ma, M., Li, Z., Gao, W., & He, Z. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0031 · Cited by 31
Kim, Y., Wang, K., Lock, R. I., Nash, T. R., Fleischer, S., Wang, B. Z., Fine, B. M., & Vunjak‐Novakovic, G. (2024) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2024.3377461 · Cited by 28
Dierickx, P., Doevendans, P. A., Geijsen, N., & Laake, L. W. V. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9391-6 · Cited by 27
A spheroid-based biosensor for the label-free detection of drug-induced field potential alterations
Daus, A. W., Layer, P. G., & Thielemann, C. (2012) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2012.02.011 · Cited by 23
Merkely, B. P., Gara, E., Lendvai, Z., Skopál, J., Leja, T., Zhou, W., Kosztin, A., Várady, G., Mioulane, M., Bagyura, Z., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0247 · Cited by 22
Self-citationStem cell and exosome therapies for regenerating damaged myocardium in heart failure
Yahyazadeh, R., Rahimi, V. B., & Askari, V. R. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122858 · Cited by 21
Reed, D. M., Földes, G., Gatheral, T. L., Paschalaki, K. E., Lendvai, Z., Bagyura, Z., Nemeth, T., Skopál, J., Merkely, B. P., Telcian, A. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091119 · Cited by 20
Self-citationDolatshad, N. F., Hellen, N., Jabbour, R. J., Harding, S. E., & Földes, G. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00076 · Cited by 20
Self-citationMilligan, G., & McGrath, J. C. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00422.x · Cited by 19
Embryonic stem cell application in drug discovery
Lou, Y., & Liang, X. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.194 · Cited by 19
Refinement, reduction and replacement approaches toin vivocardiovascular research
Emerson, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00959.x · Cited by 18
Lee, H., Kim, B. Y., Yun, J., Bae, J., Park, S., Jeon, J., Jang, H. R., Lee, J., & Lee, S. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1367141 · Cited by 14
Jawad, H., Fray, M. E., Boccaccini, A. R., Harding, S. E., Wright, J. S., Chen, Q. Z., Piegat, A., & Ali, N. N. (2010) · Advanced Engineering Materials · doi:10.1002/adem.201080078 · Cited by 14
Self-citationCardiac Gap Junction Channels Are Upregulated by Metoprolol: An Unexpected Effect of Beta-Blockers
Salameh, A., Blanke, K., Dhein, S., & Janoušek, J. (2010) · Pharmacology · doi:10.1159/000276982 · Cited by 14
Szebényi, K., Erdei, Z., Péntek, A., Sebe, A., Orbán, T. I., Sarkadi, B., & Apáti, Á. (2011) · Personalized Medicine · doi:10.2217/pme.11.19 · Cited by 13
Edge-Detection for Contractility Measurements with Cardiac Spheroids
Zuppinger, C. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6661-5_11 · Cited by 13
Tompkins, J. D., & Riggs, A. D. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1340-0 · Cited by 12
Embryonic Stem Cells for Severe Heart Failure: Why and How?
Menasché, P. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9356-9 · Cited by 11
Robotic cell manipulation with optical tweezers for biomechanical characterization
Tan, Y., Sun, D. B., Cheng, S. H., & Li, R. A. (2011) · Proceedings - IEEE International Conference on Robotics and Automation/Proceedings · doi:10.1109/icra.2011.5979577 · Cited by 10
EXTRACTION OF SULFATED GLYCOSAMINOGLYCANS FROM MACKEREL AND HERRING FISH WASTE
Raghuraman, H. (2013) · Library and Archives Canada (Government of Canada) · Cited by 10
Kondrashov, A. V., Yusof, N. A. N. M., Hasan, A., Goulding, J., Kodagoda, T., Hoang, D. M., Vo, N. T. N., Melarangi, T., Dolatshad, N. F., Gorelik, J., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.019 · Cited by 9
Self-citationCardiomyocytes from embryonic stem cells: towards human therapy
Földes, G., Harding, S. E., & Ali, N. N. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1473 · Cited by 8
Self-citationThe Promise and Therapeutic Potential of Human ES and iPS Cells
Lu, S., Lee, R. J., Napoli, C., Oh, S. K. W., Kimbrel, E. A., & Feng, Q. (2011) · Stem Cells International · doi:10.4061/2011/959275 · Cited by 8
Anand, A., Tseng, H.-C., Chiang, H., Hsu, W., Liao, Y.-F., Lu, S. H.-A., Tsai, S., Pan, C., & Chen, Y. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00584 · Cited by 6
Weiser-Bitoun, I., Mazgaoker, S., Eid, R., Brosh, I., & Yaniv, Y. (2025) · iScience · doi:10.1016/j.isci.2025.112005 · Cited by 3
Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells
Stillitano, F., Karakikes, I., & Hajjar, R. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6588-5_12 · Cited by 3
Tousi, M. S., & Sepehri, H. (2014) · Journal of chemical health risks · Cited by 3
Jiang, W., Hu, X., Li, F. R., Li, G., & Wang, Y. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265686 · Cited by 3
Pluripotent stem cell-derived cardiomyocyte transplantation: marching from bench to bedside
Yi, H., Liu, J., Wang, W., Li, H., Kong, W., Li, X., Zhang, W., Pahlavan, S., Tang, Y., Wang, X., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2801-x · Cited by 2
Moskaleva, N. E., Марсельевич, Р. П., Samoylov, V. M., Varzieva, V. G., Baskhanova, S. N., Tarasov, V. V., Smolyarchuk, Е. А., Kudlay, D. A., & Appolonova, S. A. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2025-13-2-70-83 · Cited by 2
Catalucci, D., Bang, M., & Condorelli, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707633 · Cited by 2
Array Tomography for Cardiovascular Imaging: Description of Technique and Potential Applications
Saatchi, S., Smith, S. J., & Micheva, K. D. (2012) · Wiley eBooks · doi:10.1002/9781118481585.ch78 · Cited by 1
Human Pluripotent Stem Cells and Drug Discovery: A New Beginning
Verma, V., Mehta, A. K., & Flora, S. J. S. (2016) · Defence Life Science Journal · doi:10.14429/dlsj.1.10060 · Cited by 1
Regulation of human cardiomyocyte excitation-contraction coupling by human cardiac fibroblasts
Wang, B. (2019) · Spiral (Imperial College London) · doi:10.25560/79561 · Cited by 1
Human embryonic stem cells (hESCs) for heart regeneration
Menasché, P. (2014) · Elsevier eBooks · doi:10.1533/9780857096708.3.266
Human pluripotent stem cell-based microtechnologies for in vitro modeling of cardiac diseases
Martewicz, S. (2015) · Padua@research (University of Padova)
Les cellules souches embryonnaires dans le traitement de l’insuffisance cardiaque sévère
Menasché, P. (2012) · Biologie Aujourd hui · doi:10.1051/jbio/2012002
Human embryonic stem cell-derived cardiomyocytes as a novel in vitro cardiac model system
Mioulane, M. (2011) · Spiral (Imperial College London) · doi:10.25560/6980
Raad, F. S. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5856
Gennaccaro, L. (2017) · DSpaceUnipr (University of Parma)
Duncan, G. (2017) · Nottingham ePrints (University of Nottingham)
Modeling Atrial Fibrillation using Human Embryonic Stem Cells
Laksman, Z. (2015) · TSpace (University of Toronto)
Humphrey, E. J. (2017) · Spiral (Imperial College London) · doi:10.25560/59350
Ricardo, C. P. (2017) · Spiral (Imperial College London) · doi:10.25560/61778
Hasan, A. (2020) · Spiral (Imperial College London) · doi:10.25560/88323
(2011) · Circulation · doi:10.1161/cir.0b013e3182044ce8
Faculty Opinions recommendation of A tissue-engineered scale model of the heart ventricle.
Radisic, M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733680169.793554004
Faculty Opinions recommendation of A tissue-engineered scale model of the heart ventricle.
Truskey, G. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733680169.793549351
Enhancing progenitor cells for cell therapy after myocardial infraction
Malandraki-Miller, S. (2016) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-8g255b8j9
Biowire II Platform: High Fidelity Heart-on-a-chip for Drug Screening and Disease Modeling
Zhao, Y. (2019) · TSpace (University of Toronto)
Vo, N. T. N. (2021) · Nottingham ePrints (University of Nottingham)
Wagner, T. (2010) · Qucosa (Saxon State and University Library Dresden)
Metadata
- Authors
- Brito‐Martins, M., Harding, S. E., & Ali, N. N.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Harding, S E
- ORCID
- Harding, S E
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-02
- Volume
- 153
- Issue
- 4
- Pages
- 751-759
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2259205
- OpenAlex
- W2013721243
- Cited by
- 74
- References
- 31
- Citations by year
- 2025: 3 · 2024: 3 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 7 · 2013: 2 · 2012: 10
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor, 363 d)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (G0600373/1)
- Biotechnology and Biological Sciences Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Keywords
- human embryonic stem cell-derived cardiomyocytes, beta1-adrenergic receptor, beta2-adrenergic receptor, isoproterenol, cardiomyocyte differentiation, beating frequency, heart failure, ventricular myocytes, adrenergic signaling
- MeSH terms
- Adrenergic beta-Agonists, Adrenergic beta-Antagonists, Adult, Animals, Carbachol, Cell Differentiation, Cell Line, Dose-Response Relationship, Drug, Heart Failure, Humans, Imidazoles, Isoproterenol, Myocardial Contraction, Propanolamines, Receptors, Muscarinic, Time Factors, Receptors, Adrenergic, beta-1, Receptors, Adrenergic, beta-2, Muscarinic Agonists, Cell Lineage, Myocytes, Cardiac, Stem Cell Transplantation, Mice, Embryonic Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.